As a medication indicated for the treatment of specific lymphomas, orelabrutinib may be associated with a spectrum of adverse reactions while delivering therapeutic benefits. The common and clinically notable adverse reactions include infectious pneumonia, thrombocytopenia, anemia, pulmonary inflammation, herpesvirus infection, and increased bleeding risk. Among these, thrombocytopenia may necessitate treatment interruption, dose reduction, or even permanent treatment discontinuation.
I. Common and Clinically Alerting Adverse Reactions
Some adverse reactions of orelabrutinib have a relatively high incidence rate and may present with severe manifestations, mainly including:
Infectious pneumonia
Elevated risk of pulmonary infection, which may induce symptoms such as dyspnea.
Thrombocytopenia
Reduced platelet count in the blood, leading to impaired coagulation function and increased susceptibility to bruising or bleeding.
Anemia
Decreased red blood cell count, which may cause fatigue and asthenia.
Pulmonary inflammation
Non-infectious inflammatory response in the lungs.
Herpesvirus infection
Increased risk of reactivation of viral infections such as herpes zoster.
Bleeding
Including epistaxis, gingival bleeding, or more severe bleeding events.
II. Adverse Reactions Requiring Treatment Adjustment
Dose modification may be needed if certain adverse reactions become severe:
Conditions necessitating treatment interruption
Thrombocytopenia, infectious pneumonia, pulmonary inflammation, neutropenia (leukopenia), fever, etc.
Conditions necessitating dose reduction
Neutropenia, thrombocytopenia, bleeding, etc.
Conditions necessitating treatment discontinuation
Mainly recurrent or refractory thrombocytopenia.
III. Precautions for Medication Use
Periodic monitoring of complete blood count (with focus on platelet and neutrophil levels) and signs of infection is required during treatment.
Prompt medical attention should be sought if symptoms such as fever, persistent cough, dyspnea, abnormal bleeding or bruising, and cutaneous herpes occur.
Physicians will decide whether to interrupt, reduce the dose, or permanently discontinue the medication based on the specific type and severity of adverse reactions.
Do not adjust the dosage or discontinue the medication without authorization; adverse reaction management must be strictly conducted in accordance with the physician’s instructions.
